The Role of TRAIL, IP-10 and MxA in Distinguishing Acute Community-acquired Viral and Bacterial Pneumonia in Children

Abstract

Objective

Acute paediatric community-acquired pneumonia (pedCAP) represents a significant burden on child health and highlights the need for accurate diagnostic tools. This study aimed to differentiate between acute community-acquired viral and bacterial pedCAP using TRAIL, IP-10, and MxA markers.

Material and Method

The study a single-center prospective study was conducted between January 2019 to January 2020. During the follow-up period, 315 patients with paediatric community-acquired pneumonia were followed up. The analysis was performed with 52 patients aged 5 years and younger in whom pathogens were detected. 24 control groups were also included to see the change of markers in intact subjects. The patients’ medical history and samples were obtained upon hospital admission or within the first day.

Results

The mean values of MxA, TRAIL, and IP-10 differed significantly among all three groups (all p values p<0.01). The ROC analysis indicated that serum MxA, TRAIL, and IP-10 parameters had diagnostic value in predicting the differentiation of viral pedCAP from bacterial pedCAP .

Conclusion

The TRAIL, MxA, and IP-10 markers have diagnostic value in distinguishing viral pneumonia and bacterial pneumonia. Among these markers, MxA exhibits the highest sensitivity. High levels of MxA, TRAIL and IP-10 in combination with low C-reactive protein (CRP), procalcitonin (PCT) and neutrophil lymphocyte ratio (NLR) values to differentiate viral from bacterial pedCAP will significantly contribute to the accurate identification of viral LRTI.

Zusammenfassung

Zielsetzung

Die akute pädiatrische ambulant erworbene Lungenentzündung (pedCAP) stellt eine erhebliche Belastung für die Gesundheit von Kindern dar und unterstreicht den Bedarf an präzisen Diagnoseinstrumenten. Diese Studie zielte darauf ab, anhand von TRAIL-, IP-10- und MxA-Markern zwischen akuter ambulant erworbener viraler und bakterieller pedCAP zu unterscheiden.

Material und Methode

Die Studie, eine einzentrale prospektive Studie, wurde zwischen Januar 2019 und Januar 2020 durchgeführt. Während des Nachbeobachtungszeitraums wurden 315 Patienten mit pädiatrischer ambulant erworbener Pneumonie nachbeobachtet. Die Analyse wurde mit 52 Patienten im Alter von 5 Jahren und jünger durchgeführt, bei denen Erreger nachgewiesen wurden. Außerdem wurden 24 Kontrollgruppen einbezogen, um die Veränderung der Marker bei unverletzten Personen zu untersuchen. Die Anamnese der Patienten und die Proben wurden bei der Aufnahme ins Krankenhaus oder innerhalb des ersten Tages entnommen.

Ergebnisse

Die Mittelwerte von MxA, TRAIL und IP-10 unterschieden sich signifikant zwischen allen drei Gruppen (alle p-Werte p<0,01). Die ROC-Analyse zeigte, dass die Serumparameter MxA, TRAIL und IP-10 einen diagnostischen Wert für die Unterscheidung zwischen viraler und bakterieller pedCAP haben.

Schlussfolgerung

Die Marker TRAIL, MxA und IP-10 haben einen diagnostischen Wert bei der Unterscheidung zwischen viraler und bakterieller Lungenentzündung. Unter diesen Markern weist MxA die höchste Sensitivität auf. Hohe MxA-, TRAIL- und IP-10-Werte in Kombination mit niedrigen C-reaktiven Protein- (CRP), Procalcitonin- (PCT) und Neutrophilen-Lymphozyten-Verhältnis- (NLR) Werten zur Unterscheidung von viraler und bakterieller pädiatrischer Pneumonie werden wesentlich zur genauen Identifizierung von viraler LRTI beitragen.

Keywords

myxovirus resistance protein 1 (MxA) - tumor necrosis factor- related - apoptosıs-inducing ligand (TRAIL) - interferon-γ-induced protein (IP-10). - Acute paediatric community-acquired pneumonia (pedCAP)

Schlüsselwörter

Myxovirus-Resistenzprotein 1 - Tumor-Nekrose-Faktor-verwandter - Apoptosıs-induzierender Ligand - Interferon-γ-induziertes Protein - Akute pädiatrische - in der Gemeinschaft erworbene Lungenentzündung (pedCAP)

Publikationsverlauf

Artikel online veröffentlicht:
14. Juli 2025

• References

• 1 World Health Organization. Revised WHO classification and treatment of pneumonia in children at health facilities: evidence summaries. Geneva: World Health Organization; 2014
• 2 Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Ther Adv Drug Saf 2014; 5: 229-41
• 3 Ashwin Singh Chouhan. Overuse of Antibiotics Causes Serious Adverse Effects in the Body: A Literature Review. J Clin Med Health Care 2024; 1: 1-4
• 4 Shirley M. FebriDx^®: A Rapid Diagnostic Test for Differentiating Bacterial and Viral Aetiologies in Acute Respiratory Infections. Mol Diagn Ther 2019; 23: 803-809
• 5 Van Houten CB, de Groot JAH, Klein A. et al. A host-protein based assay to differentiate between bacterial and viral infections in preschool children (OPPORTUNITY): a double-blind, multicentre, validation study. Lancet Infect Dis 2017; 17: 431-40
• 6 Iliopoulou K, Koufargyris P, Doulou S. et. al Developing a Tool for Differentiation Between Bacterial and Viral Respiratory Infections Using Myxovirus Resistance Protein A and C-Reactive Protein. Infect Dis Ther 2024; 13: 105-119
• 7 Papan C, Argentiero A, Adams O. et. al Association of viral load with TRAIL, IP-10, CRP biomarker signature and disease severity in children with respiratory tract infection or fever without source: A prospective, multicentre cohort study. J Med Virol 2023; 95: e28113
• 8 Harris M, Clark J, Coote N. et. al A; British Thoracic Society Standards of Care Committee. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011; 66: ii1-23
• 9 Nascimento-Carvalho CM. Community-acquired pneumonia among children: the latest evidence for an updated management. J Pediatr (Rio J) 2020; 96: 29-38
• 10 Ruuskanen O, Lahti E, Jennings LC. et. al Viral pneumonia. Lancet. 2011; 9 377: 1264-75
• 11 Nakabayashi M, Adachi Y, Itazawa T. et al. MxA-based recognition of viral illness in febrile children by a whole 104 blood assay. Pediatr Res 2006; 60: 770-4
• 12 DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44: 837-4
• 13 Bard J.D., McElvania E. Panels and syndromic testing in clinical microbiology. Clinics in laboratory medicine 2020; 40: 393-420
• 14 Sambursky R, Shapiro N. Evaluation of a combined MxA and CRP point-of- care immunoassay to identify viral and/or bacterial immune response in patients with acute febrile respiratory infection. Eur Clin Respir J. 2015; 2: 28245
• 15 Joseph P, Godofsky E. Outpatient antibiotic stewardship: A growing frontier- combining myxovirus resistance protein a with other biomarkers to improve antibiotic use. Infect Dis 2018; 5
• 16 Piri R, Yahya M, Ivaska L. et. al Myxovirus Resistance Protein A as a Marker of Viral Cause of Illness in Children Hospitalized with an Acute Infection. Microbiol Spectr 2022; 10: e0203121
• 17 Rhedin S, Eklundh A, Ryd-Rinder M. et. al Myxovirus resistance protein A for discriminating between viral and bacterial lower respiratory tract infections in children – The TREND study. Clin Microbiol Infect 2022; 28: 1251-1257
• 18 Papan C, Argentiero A, Porwoll M. et. al A host signature based on TRAIL, IP-10, and CRP for reducing antibiotic overuse in children by differentiating bacterial from viral infections: a prospective, multicentre cohort study. Clin Microbiol Infect 2022; 28: 723-730
• 19 Fröhlich F, Gronwald B, Bay J. et. al Expression of TRAIL, IP-10, and CRP in children with suspected COVID-19 and real-life impact of a computational signature on clinical decision-making: a prospective cohort study. Infection. 2023; 51: 1349-1356
• 20 Leticia Fernandez-Carballo B, Escadafal C, MacLean E. et. al Distinguishing bacterial versus non-bacterial causes of febrile illness – A systematic review of host biomarkers. J Infect 2021; 82: 1-10
• 21 Ashkenazi-Hoffnung L, Oved K, Navon R. et al. A host-protein signature is superior to other biomarkers for differentiating between bacterial and viral disease in patients with respiratory infection and fever without source: a prospective observational study. Eur J Clin Microbiol Infect Dis 2018; 37: 1361-71
• 22 van der Does Y, Tjikhoeri A, Ramakers C. et. al TRAIL and IP-10 as biomarkers of viral infections in the emergency department. J Infect 2016; 72: 761-763
• 23 Gunaratnam LC, Robinson JL, Hawkes MT. Systematic Review and Meta-Analysis of Diagnostic Biomarkers for Pediatric Pneumonia. J Pediatric Infect Dis Soc 2021; 27 10: 891-900
• 24 Cao XS, Zheng WQ, Hu ZD. Diagnostic value of soluble biomarkers for parapneumonic pleural effusion. Crit Rev Clin Lab Sci 2023; 60: 233-247
• 25 Drummond P, Clark J, Wheeler J. et. al Community acquired pneumonia – A prospective UK study. Arch Dis Child 2000; 83: 408-12
• 26 Gauchan E, Adhikari S. C-reactive Protein Versus Neutrophil/lymphocyte Ratio in Differentiating Bacterial and Non-bacterial Pneumonia in Children. J Nepal Health Res Counc 2016; 14: 154-8
• 27 Bekdas M, Goksugur SB, Erkoçoğlu M. et. al Neutrophil/lymphocyte and C-reactive protein/mean platelet volume ratios in differentiating between viral and bacterial pneumonias and diagnosing early complications in children. Saudi Med J 2014 2014; 35: 442-7